Influence of Dosing Times on Cisplatin-induced Peripheral Neuropathy in Rats

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2016 Sep 29

PMID 27678475

Citations 7

Authors

Yoshihiro Seto

Fumiyasu Okazaki

Keiji Horikawa

Jing Zhang

Hitoshi Sasaki

Hideto To

Affiliations

Soon will be listed here.

Abstract

Background: Although cis-diamminedichloro-platinum (CDDP) exhibits strong therapeutic effects in cancer chemotherapy, its adverse effects such as peripheral neuropathy, nephropathy, and vomiting are dose-limiting factors. Previous studies reported that chronotherapy decreased CDDP-induced nephropathy and vomiting. In the present study, we investigated the influence of dosing times on CDDP-induced peripheral neuropathy in rats.

Methods: CDDP (4 mg/kg) was administered intravenously at 5:00 or 17:00 every 7 days for 4 weeks to male Sprague-Dawley rats, and saline was given to the control group. To assess the dosing time dependency of peripheral neuropathy, von-Frey test and hot-plate test were performed.

Results: In order to estimate hypoalgesia, the hot-plate test was performed in rats administered CDDP weekly for 4 weeks. On day 28, the withdrawal latency to thermal stimulation was significantly prolonged in the 17:00-treated group than in the control and 5:00-treated groups. When the von-Frey test was performed to assess mechanical allodynia, the withdrawal threshold was significantly lower in the 5:00 and 17:00-treated groups than in the control group on day 6 after the first CDDP dose. The 5:00-treated group maintained allodynia throughout the experiment with the repeated administration of CDDP, whereas the 17:00-treated group deteriorated from allodynia to hypoalgesia.

Conclusions: It was revealed that the severe of CDDP-induced peripheral neuropathy was inhibited in the 5:00-treated group, whereas CDDP-treated groups exhibited mechanical allodynia. These results suggested that the selection of an optimal dosing time ameliorated CDDP-induced peripheral neuropathy.

Citing Articles

Neuroprotective Effects of Trimetazidine against Cisplatin-Induced Peripheral Neuropathy: Involvement of AMPK-Mediated PI3K/mTOR, Nrf2, and NF-B Signaling Axes.

Elbaset M, Afifi S, Esatbeyoglu T, Abdelrahman S, Saleh D Oxid Med Cell Longev. 2024; 2024:6612009.

PMID: 39502494 PMC: 11535264. DOI: 10.1155/2024/6612009.

Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds.

Marcu L Pharmaceuticals (Basel). 2022; 15(2).

PMID: 35215367 PMC: 8876358. DOI: 10.3390/ph15020255.

Autophagy Promotes the Survival of Adipose Mesenchymal Stem/Stromal Cells and Enhances Their Therapeutic Effects in Cisplatin-Induced Liver Injury via Modulating TGF-β1/Smad and PI3K/AKT Signaling Pathways.

El Nashar E, Alghamdi M, Alasmari W, Hussein M, Hamza E, Taha R Cells. 2021; 10(9).

PMID: 34572126 PMC: 8470434. DOI: 10.3390/cells10092475.

Effect of intrathecal administration of exogenous noggin on neuropathic pain.

Zhang W, Liu C, Wang X, Xu J, Yang L Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2021; 46(7):673-679.

PMID: 34382582 PMC: 10930133. DOI: 10.11817/j.issn.1672-7347.2021.200715.

Efficacy and Safety of Systemic and Locoregional Cisplatin Chronotherapy in Rats with Ovarian Carcinoma.

Kireeva G, Gubareva E, Maydin M, Osetnik V, Kruglov S, Panchenko A Onco Targets Ther. 2021; 14:3373-3381.

PMID: 34079283 PMC: 8163628. DOI: 10.2147/OTT.S309285.

References

Oda M, Koyanagi S, Tsurudome Y, Kanemitsu T, Matsunaga N, Ohdo S . Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice. Mol Pharmacol. 2014; 85(5):715-22. DOI: 10.1124/mol.113.089805. View

Rao R, Flynn P, Sloan J, Wong G, Novotny P, Johnson D . Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer. 2008; 112(12):2802-8. DOI: 10.1002/cncr.23482. View

Aloe L, Manni L, Properzi F, De Santis S, Fiore M . Evidence that nerve growth factor promotes the recovery of peripheral neuropathy induced in mice by cisplatin: behavioral, structural and biochemical analysis. Auton Neurosci. 2001; 86(1-2):84-93. DOI: 10.1016/S1566-0702(00)00247-2. View

Cavaletti G, Marzorati L, Bogliun G, Colombo N, Marzola M, Pittelli M . Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992; 69(1):203-7. DOI: 10.1002/1097-0142(19920101)69:1<203::aid-cncr2820690133>3.0.co;2-1. View

Levi F, Hrushesky W, Halberg F, Langevin T, Haus E, Kennedy B . Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. Eur J Cancer Clin Oncol. 1982; 18(5):471-7. DOI: 10.1016/0277-5379(82)90116-x. View

Cata J, Weng H, Dougherty P . Behavioral and electrophysiological studies in rats with cisplatin-induced chemoneuropathy. Brain Res. 2008; 1230:91-8. PMC: 2630495. DOI: 10.1016/j.brainres.2008.07.022. View

Lomonaco M, Milone M, Batocchi A, Padua L, Restuccia D, Tonali P . Cisplatin neuropathy: clinical course and neurophysiological findings. J Neurol. 1992; 239(4):199-204. DOI: 10.1007/BF00839140. View

Ta L, Bieber A, Carlton S, Loprinzi C, Low P, Windebank A . Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain. 2010; 6:15. PMC: 2848188. DOI: 10.1186/1744-8069-6-15. View

Levi F, Zidani R, Misset J . Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet. 1997; 350(9079):681-6. DOI: 10.1016/s0140-6736(97)03358-8. View

10.

Woods R, Williams C, Levi J, Page J, Bell D, Byrne M . A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer. 1990; 61(4):608-11. PMC: 1971367. DOI: 10.1038/bjc.1990.135. View

11.

Roila F, Ruggeri B, Ballatori E, Fatigoni S, Caserta C, Licitra L . Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol. 2015; 26(6):1248-1253. DOI: 10.1093/annonc/mdv132. View

12.

Kobayashi M, To H, Yuzawa M, Hakamata Y, Higuchi S, Tokue A . Effects of dosing time and schedule on cisplatin-induced nephrotoxicity in rats. J Pharm Pharmacol. 2000; 52(10):1233-7. DOI: 10.1211/0022357001777360. View

13.

Levi F, Hrushesky W, Blomquist C, Lakatua D, Haus E, Halberg F . Reduction of cis-diamminedichloroplatinum nephrotoxicity in rats by optimal circadian drug timing. Cancer Res. 1982; 42(3):950-5. View

14.

Hayes D, Cvitkovic E, GOLBEY R, Scheiner E, Helson L, KRAKOFF I . High dose cis-platinum diammine dichloride: amelioration of renal toxicity by mannitol diuresis. Cancer. 1977; 39(4):1372-81. DOI: 10.1002/1097-0142(197704)39:4<1372::aid-cncr2820390404>3.0.co;2-j. View

15.

McDonald E, Randon K, Knight A, Windebank A . Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005; 18(2):305-13. DOI: 10.1016/j.nbd.2004.09.013. View

16.

Seynaeve C, Schuller J, Buser K, Porteder H, Van Belle S, Sevelda P . Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomised, parallel group study..... Br J Cancer. 1992; 66(1):192-7. PMC: 1977922. DOI: 10.1038/bjc.1992.241. View

17.

Park H, Stokes J, Corr M, Yaksh T . Toll-like receptor signaling regulates cisplatin-induced mechanical allodynia in mice. Cancer Chemother Pharmacol. 2013; 73(1):25-34. PMC: 3917999. DOI: 10.1007/s00280-013-2304-9. View

18.

Kang Y, Park Y, Ryoo B, Bang Y, Cho K, Shin D . Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron. J Int Med Res. 2002; 30(3):220-9. DOI: 10.1177/147323000203000302. View

19.

Martoni A, Angelelli B, Guaraldi M, Strocchi E, Pannuti F . An open randomised cross-over study on granisetron versus ondansetron in the prevention of acute emesis induced by moderate dose cisplatin-containing regimens. Eur J Cancer. 1996; 32A(1):82-5. DOI: 10.1016/0959-8049(95)00519-6. View

20.

Tabuchi M, To H, Sakaguchi H, Goto N, Takeuchi A, Higuchi S . Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. Cancer Res. 2005; 65(18):8448-54. DOI: 10.1158/0008-5472.CAN-05-1161. View